Bisphenol A at Low Nanomolar Doses Confers Chemoresistance in Estrogen Receptor-α–Positive and –Negative Breast Cancer Cells

Elizabeth W. LaPensee, Traci R. Tuttle, Sejal R. Fox, and Nira Ben-Jonathan

Department of Cancer and Cell Biology, University of Cincinnati, Cincinnati, Ohio, USA

BACKGROUND: Resistance to chemotherapy is a major problem facing breast cancer patients, and identifying potential contributors to chemoresistance is a critical area of research. Bisphenol A (BPA) has long been suspected to promote carcinogenesis, but the high doses of BPA used in many studies generated conflicting results. In addition, the mechanism by which BPA exerts its biological actions is unclear. Although estrogen has been shown to antagonize anticancer drugs, the role of BPA in chemoresistance has not been examined.

OBJECTIVE: The objective of our study was to determine whether BPA at low nanomolar concentrations opposes the action of doxorubicin, cisplatin, and vinblastine in the estrogen receptor-α (ERα)-positive T47D and the ERβ-negative MDA-MB-468 breast cancer cells.

METHODS: We determined the responsiveness of cells to anticancer drugs and BPA using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) cytotoxicity assay. Specific ERα and ERβ inhibitors and real-time polymerase chain reaction were used to identify potential receptor(s) that mediate the actions of BPA. Expression of antiapoptotic proteins was assessed by Western blotting.

RESULTS: BPA antagonizes the cytotoxicity of multiple chemotherapeutic agents in both ERα-positive and -negative breast cancer cells independent of the classical ERs. Both cell types express alternative ERs, including G-protein–coupled receptor 30 (GPR30) and members of the estrogen-related receptor family. Increased expression of antiapoptotic proteins is a potential mechanism by which BPA exerts its anticytotoxic effects.

CONCLUSIONS: BPA at environmentally relevant doses reduces the efficacy of chemotherapeutic agents. These data provide considerable support to the accumulating evidence that BPA is hazardous to human health.

KEY WORDS: bisphenol A, breast cancer cells, chemotherapeutic agents, cytotoxicity, estrogen receptors. Environ Health Perspect 117:175–180 (2009). doi:10.1289/ehp.11788 available via http://dx.doi.org/ [Online 8 October 2008]

Bisphenol A (BPA) is a monomer of polycarbonate plastics that is used in numerous consumer products, including food and water containers, baby bottles, linings of metal food and beverage cans, medical tubing, epoxy resins, and dental fillings (Welshons et al. 2006). Small amounts of BPA can be liberated from incompletely polymerized polycarbonates or via partial hydrolysis, especially upon heating (Le et al. 2008). Decades of continuous release of free BPA into food, beverages, and the environment have resulted in widespread human exposure to this chemical. Many studies in the United States, Europe, and Japan have documented BPA levels ranging from 0.2 to 10 ng/mL (~0.5–40 nM) in adult and fetal human serum (Welshons et al. 2006) as well as in breast milk (Kuruto-Niwa et al. 2007). Being lipophilic, BPA can also accumulate in fat, and detectable levels of BPA have been found in half of breast adipose tissue samples examined (Fernandez et al. 2007).

Given the structural similarity of BPA to the potent estrogenic compound diethylstilbestrol, BPA’s ability to promote carcinogenesis has long been suspected (Keri et al. 2007). Studies with rodents have revealed that early-life exposure to BPA causes increased susceptibility to mammary and prostate tumorogenesis (Prins et al. 2007; Soto et al. 2008), but there is less evidence for carcinogenic activity of BPA when administered to adult animals. Studies with human breast cancer cells have yielded inconsistent data with respect to the mitogenic, apoptotic, and transcriptional properties of BPA (Dairkee et al. 2008; Diel et al. 2002; Singleton et al. 2006; Soto et al. 1995). This inconsistency is attributed to the wide variations in BPA doses used, some of which are at micromolar levels. BPA often exhibits a U-shaped or an inverted U-shaped dose–response curve. Consequently, extrapolation from an action, or lack of action, of BPA at high doses to its presumed bioactivity at low doses is unwarranted. Thus, to support the argument that BPA poses risks to human health, it is necessary to establish its effectiveness at environmentally relevant concentrations (the low nanomolar range).

The mechanism by which BPA exerts its biological actions is enigmatic. The binding affinity of BPA to estrogen receptor-α (ERα) or ERβ is 10,000- and 1,000-fold lower than that of estradiol (E2), respectively (Kuiper et al. 1998). This suggests that BPA should mimic or compete with endogenous estrogens only at the micromolar range. Yet, BPA at nanomolar doses often displays activities that are similar to those of E2 (Watson et al. 2005; Welshons et al. 2006). To reconcile this dilemma, several speculations have been proposed. One view is that BPA binds differently within the ligand-binding domain of ERα or ERβ and recruits a dissimilar set of co-regulators (Safe et al. 2002). Other investigators maintain that BPA elicits its responses via nonclassical ERs, including membrane-anchored ERs (Watson et al. 2005), G-protein–coupled receptor 30 (GPR30; Thomas and Dong 2006), and members of the estrogen-related receptors (ERRs) such as ERRγ, which has a high binding affinity to BPA (Okada et al. 2008).

Although most studies to date have examined whether BPA stimulates breast cancer cell proliferation, its potential effects on chemotherapeutic efficacy have received little attention. Chemotherapy, alone or in combination with hormonal or targeted therapy, remains the mainstay treatment in metastatic breast disease. A wide variety of anticancer drugs are available, including doxorubicin, cisplatin, and vinblastine. Most regimens combine agents that act by different mechanisms to improve efficacy. Although treatment of breast cancer patients with these anticancer drugs has shown good success, tumor resistance remains a major obstacle. Some tumors are intrinsically resistant to certain drugs, whereas others can acquire resistance after treatment. Although the effects of environmental pollutants on drug transporters as well as on metabolic and detoxifying enzymes have been explored to some extent (Brockmoller et al. 2000; Chen et al. 1998; Han and Zhang 2004), there is no information on whether endocrine disruptors can modulate the responsiveness of breast cancer cells to anticancer drugs.

The objectives of this study were to a) compare the effects of low doses of BPA on cisplatin, doxorubicin, and vinblastine cytotoxicity in the estrogen-responsive T47D breast cancer cells; b) examine whether BPA exerts similar effects on the estrogen-insensitive MDA-MB-468 breast cancer cells; c) compare...
expression of classical (ERα and ERβ) and nonclassical (GPR30, ERα, ERβ, and ERRγ) ERs in the two cell lines; d) determine the effects of the ER antagonist ICI182,780 (ICI) and the ERβ-specific antagonist 4-[2-
phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP) on the ability of BPA to antagonize the cytotoxic effects of doxorubicin; and e) examine whether the chemoresistant effects of BPA are mediated by altered expression of antiapoptotic/proapoptotic
proteins of the Bcl-2 and survivin families.

Materials and Methods

Drugs and inhibitors. Doxorubicin (Sigma, St. Louis, MO), cisplatin (Sigma), and vinblastine (Biomol, Plymouth Meeting, PA) were dissolved in dimethyl sulfoxide (DMSO; 100 mM) and ethanol (50 mM), respectively. Drugs and inhibitors were diluted in culture medium immediately before treatment.

Cell lines and culture conditions. We obtained T47D and MDA-MB-468 cells from the American Type Culture Collection (Manassas, VA). T47D cells were maintained in RPMI medium (HyClone, Logan, UT) supplemented with 10% fetal bovine serum (FBS; HyClone), 1 mM sodium pyruvate, and 50 µg/mL normocin (InvivoGen, San Diego, CA). MDA-MB-468 cells were cultured in low-glucose Dulbecco’s modified Eagle’s medium (DMEM; HyClone) supplemented with 10% FBS and 50 µg/mL normocin. For all experiments, T47D cells were plated in phenol red-free RPMI with 5% charcoal-stripped serum (CSS) and ITS+ supplement (1:200; BD Biosciences, Bedford, MA) and treated in RPMI with 3% CSS and ITS+. MDA-MB-468 cells were plated in phenol red-free DMEM supplemented with 5% CSS and treated in DMEM with 1% CSS.

Cytotoxicity assay. Cells were plated at a density of 6,000 or 8,000 cells/well in 96-well plates in plating medium. The next day, cells were incubated with BPA for 24 hr in treatment medium. In the case of inhibitors, ICI and PHTPP were added to the cells 1 hr before BPA. After BPA treatment for 24 hr, the various drugs were added for an additional 1–4 days in the continuous presence of BPA. We determined cytotoxicity using 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT). MTT was added at a final concentration of 0.5 mg/mL for 2 hr. After medium aspiration, the formazan dye was extracted with DMSO and absorbance was read at 570 nm using a plate reader (BioTek, Winooski, VT).

Western blotting. After treatment, we homogenized cells in buffer (10 nM Tris-HCl, 5 mM EDTA, 50 mM NaCl, 50 mM sodium fluoride, 30 mM sodium pyrophosphate, 1% Triton-X, 200 µM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 1 µg/mL pepstatin, 2 µg/mL leupeptin, 5 µg/mL aprotinin). The protein concentration was determined using the Pierce (Rockford, IL) BCA (bicinchoninic acid) protein assay. Cell lysates (40 µg protein) were electrophoresed onto 12% or 15% sodium dodecyl sulfate polyacrylamide gel electrophoresis gels. After transfer to polyvinyl difluoride membranes, samples were blocked in 5% dry milk and incubated overnight with the following primary antibodies: Bcl-2, Bcl-xL, survivin (1:1,000 each; Cell Signaling, Danvers, MA), ERα (1:400; Santa Cruz Biotechnology, Santa Cruz, CA), ERβ

Table 1. Human gene-specific primers for quantitative real-time reverse-transcriptase PCR.

| Gene   | Accession no. | Forward primer (5’→3’) | Reverse primer (5’→3’) | Product size (bp) |
|--------|---------------|------------------------|------------------------|-------------------|
| ESR1   | NM_000125     | CAGGACAATTGGTAATACAAAAGG | CAAGGAATGGCAATGAGTAGAG | 195               |
| ESR2   | NM_001437     | CATGTTATACATCTGTATGCC   | ACTCTCAATGTACCCCGA     | 208               |
| ESR3   | NM_004451     | ACTCAAGGATGAACTGCTG     | TGACAGAATGCTAATG       | 185               |
| ESR4   | NM_004452     | CTGGTCGAATGACTGAGAGG    | TACATGGAATGAGGAATG     | 172               |
| ESR6   | NM_001438     | CATTATGCGCTTCTGCAA      | GACGAAATGCTACAAAGCA    | 122               |
| ESR10  | NM_001396     | GCAAGATGCTGAAATCGCAAA  | ATCGAGTGGAGTGATG       | 153               |
| B2M    | NM_004048     | GCAATTC GCCAAGCC         | GAAATTTGGAATGACCTG     | 114               |

Abbreviations: ESR1, ERα; ESR2, ERβ; ESR3, ERRα; ESR4, ERRβ; ESR6, ERRγ (all three transcripts). Primer pairs were designed using the PeriPrimer (Marshall 2004) and are all intron-spanning pairs.

*GenBank accession numbers (National Center for Biotechnology Information 2008).

![Figure 1](image1.png)

**Figure 1.** BPA protects T47D cells from several chemotherapeutic agents. Cells were treated with BPA for 24 hr, followed by increasing concentrations of doxorubicin (Dox; A), cisplatin (Cis; B), or vinblastine (Vin; C) for an additional 96 hr. Cytotoxicity was determined by the MTT assay. Values are mean ± SE of six replicates of a single experiment, repeated three times with similar results.

* p < 0.05 compared with control. ** p < 0.05 compared with the corresponding drug dose.

![Figure 2](image2.png)

**Figure 2.** BPA antagonizes anticancer drugs in MDA-MB-468 cells. Cells were treated with BPA for 24 hr, followed by increasing concentrations of doxorubicin (Dox; A), cisplatin (Cis; B), or vinblastine (Vin; C) for an additional 96 hr. Cytotoxicity was determined by the MTT assay. Values are mean ± SE of six replicates of a single experiment, repeated three times with similar results.

* p < 0.05 compared with control. ** p < 0.05 compared with the corresponding drug dose.
cells, doxorubicin treatment resulted in a dose-dependent decrease in MDA-MB-468 cell viability. BPA completely or partially protected the cells from all doses of doxorubicin. MDA-MB-468 cells were significantly more sensitive to cisplatin than were T47D cells, with the 400 ng/mL dose of cisplatin inhibiting cell viability by >80%. All doses of cisplatin were antagonized by a pretreatment with BPA. BPA protected MDA-MB-468 cells only from the lowest dose of vinblastine. Unlike in T47D cells, BPA alone had no effect on cell viability.

**BPA, at low nanomolar concentrations, protects cells from doxorubicin-induced cytotoxicity.** The next experiment evaluated the ability of increasing, environmentally relevant doses of BPA to antagonize the cytotoxic effect of one dose of doxorubicin. Figure 3 shows that BPA alone (1 nM or 10 nM) significantly increased cell viability in T47D cells but not in MDA-MB-468 cells. In both cell types, doxorubicin treatment induced an approximately 35% decrease in cell viability. A 24-hr pretreatment with BPA at all doses examined completely protected the cells from doxorubicin-induced cytotoxicity.

**The protective effects of BPA are not mediated via classical ERs.** To determine if the protective effects of BPA involved ERα or ERβ, we used ICI, an antagonist of both receptors, as well as PHTPP, a specific ERβ antagonist. As shown in Figure 4A, neither ICI nor PHTPP had any effect by themselves...
on T47D or MDA-MB-468 cell viability. Furthermore, the ability of BPA to antagonize doxorubicin-induced cytotoxicity in either cell line was not altered in the presence ofICI or PHTPP. Using Western blotting, we next probed for both ERα and ERβ in T47D and MDA-MB-468 cells treated for 1, 4, or 48 hr with the above inhibitors. Figure 4B demonstrates that T47D cells, but not MDA-MB-468 cells, express ERβ, whereas both cell types express ERα. Treatment with ICI caused a time-dependent decrease in ERα expression in T47D cells, reducing it to an undetectable level by 48 hr. On the other hand, ERβ expression in MDA-MB-468 cells increased at 4 hr and decreased after 48 hr in response to ICI treatment. PHTPP had no effect on ERα, increased the expression of ERβ in T47D cells, and had no effect on ERβ in MDA-MB-468 cells.

**Relative receptor expression in T47D and MDA-MB-468 cells.** Using real-time PCR, we compared the expression of several putative ERs in the two cell lines, as percentage of ERα expression in T47D cells. Figure 5 shows that the expression of ERβ was similar in the two cell lines, being <1% that of ERα. ERRβ is the most highly expressed of the alternative receptors in both cell lines, nearing 10% of ERα in T47D cells. The expression levels of GPR30 and ERRα are similar in T47D cells, with ERRα slightly higher than GPR30 in MDA-MB-468 cells. ERRβ was undetectable in both cell lines.

**BPA may promote chemoresistance by altering proapoptotic proteins.** We next explored the effects of BPA and doxorubicin on the expression of several prosurvival proteins. As shown in Figure 6, treatment of T47D cell with BPA for 24 hr increased both Bcl-2 and Bcl-xL expression. BPA and doxorubicin alone increased expression of survivin, but their combination had no further effect. Both doses of doxorubicin caused a small decrease in Bcl-2 expression, which was partially prevented when cells were pretreated with BPA. In MDA-MB-468 cells, Bcl-2 expression was higher when cells were exposed to 75 ng/mL doxorubicin and BPA compared with 75 ng/mL doxorubicin alone. BPA alone did not increase the expression of Bcl-xL in MDA-MB-468 cells. In both cell lines, Bcl-xL expression was higher in cells treated with 150 ng/mL doxorubicin and BPA compared with 150 ng/mL doxorubicin alone. Survivin expression was increased in both cell types in response to BPA or doxorubicin alone but was not further augmented by their combination.

**Discussion**

This is the first report that BPA antagonizes chemotherapeutic agents in both ERα-positive and -negative breast cancer cells. Importantly, unlike some previous studies that have used micromolar concentrations of BPA, we obtained our data using low nanomolar concentrations, which are relevant to human exposure levels. BPA confers chemoresistance to the anticancer drugs doxorubicin, cisplatin, and vinblastine, which act by different mechanisms. As judged by specific ERα/ERβ antagonists, BPA does not appear to mediate its effects through either ERα or ERβ. Given that both cell lines express nonclassical ERs such as GPR30 and members of the ERR family, these could serve as putative BPA receptors. The ability of BPA to alter the expression of Bcl-2 and Bcl-xL suggests a potential mechanism by which it confers chemoresistance in the two breast cancer cell lines.

We postulated that BPA might play a role in chemoresistance based on reports that E2 antagonizes anticancer drugs. For example, taxol-induced cytotoxicity in MCF-7 breast cancer cells was abrogated by 0.1 µM E2 (Huang et al. 1997). This was confirmed in a later study implicating JNK activation in the modulation of apoptosis and E2 protection (Razandi et al. 2000). In addition, E2 antagonizes doxorubicin-induced cytotoxicity in MCF-7 cells (Teixeira et al. 1995). Our data show that BPA protects T47D cells from several anticancer drugs. More unexpected was the effect of BPA on the estrogen-unresponsive MDA-MB-468 cells, raising the prospect that ERα does not mediate the chemoresistant effects of BPA.

The few reports on the effects of BPA on mitogenesis have used the ER-positive MCF-7 cells. Olsen et al. (2003) observed increased MCF-7 cell proliferation in response to BPA, with a relative proliferative potential 60,000 times lower than that of E2. Samuels et al. (2001) further confirmed such effects of BPA; their MCF-7 data are a prime example of an inverted U-shaped curve that is often observed when treating cells with increasing doses of BPA. In that study, cell proliferation was unchanged in the presence of 10 nM BPA, increased >40% with 100 nM BPA, peaked with 1 µM BPA, and declined at higher doses. These studies are in agreement with our data, which show an approximate 25% increase in cell viability in T47D cells in response to BPA. Despite the lack of a mitogenic effect of BPA in MDA-MB-468 cells, we observed its ability to antagonize the anticancer drugs with as little as 0.01 nM BPA.

Of particular interest is the ability of BPA to antagonize the cytotoxic effects of three chemotherapeutic agents that induce cell death by different mechanisms. Doxorubicin causes DNA damage by chelating metal ions, generating free radicals, and inhibiting topoisomerase II, thereby blocking transcription (Aubel-Sadron and Londos-Gagliardi 1984). Cisplatin, a platinum-based compound, causes DNA intrastrand cross-linking and inhibits replication (Stewart 2007). Vinblastine acts by interfering with microtubule dynamics, resulting in mitotic arrest and cell death (Toso et al. 1993). As mentioned above, E2

![Figure 5](image_url) **Figure 5.** T47D and MDA-MB-468 cells express several types of ERs, as determined by real-time PCR. Both cell lines express ERβ, as well as nonclassical ERs such as GPR30, ERRα, and ERRβ. Data are percentages of ERα expression in T47D cells after corrections for β-actin. Values are mean ± SE of five separate experiments.

![Figure 6](image_url) **Figure 6.** BPA may mediate chemoresistance by altering the expression of prosurvival proteins. Cells were pretreated with 10 nM BPA for 24 hr, followed by exposure to doxorubicin (Dox) 75–150 ng/mL for an additional 24 hr. Western blots were probed for Bcl-2, Bcl-xL, and survivin, with β-actin serving as a loading control. Shown are representative blots, repeated at least three times.
proteins and survivin, a prosurvival inhibitor of apoptosis, are major players in tumor growth and resistance to cytotoxic insults. Estrogen increases Bcl-2 protein expression in MCF-7 cells, with cells transfected with Bcl-2 antisense twice as sensitive to doxorubicin treatment in the presence of estrogen compared with controls (Teixeira et al. 1995). Another study suggested that increased Bcl-2 in response to estrogen protects cells from taxol-induced cytotoxicity (Huang et al. 1997). Our data indicate that up-regulation of Bcl-2 and Bcl-xL is a plausible mechanism by which BPA confers resistance to doxorubicin and possibly other anticancer drugs. The survivin data agree with another study that found increased expression of this protein after doxorubicin treatment (Tirro et al. 2006). However, the contributions of survivin are less critical when proteins such as Bcl-2 and Bcl-xL, which are upstream of survivin, mediate survival.

In conclusion, we have shown that low doses of BPA confer chemoresistance to multiple anticancer drugs, possibly by increasing expression of pro-survival Bcl-2-like proteins in breast cancer cells. Importantly, we observed the effects of BPA in a cell line lacking ERα, indicating that BPA acts via nonclassical receptors. These data highlight a previously unrecognized function of BPA in cancer management, thereby adding strong support to the growing recognition of the adverse effects of BPA on human health.

**References**

Ariazi EA, Jordan VC. 2006. Estrogen-related receptors as emerging targets in cancer and metabolic disorder. Curr Top Med Chem 6:230–235.

Aubel-Sadoun G, Landos-Gagliardi D. 1994. Daunorubin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie 66:333–352.

Brockmoller J, Cascarli I, Henning S, Meisel C, Ruots I. 2000. Molecular genetics of cancer susceptibility. Pharmacology 61:212–227.

Chen X, Cristinios GD, Batist G. 1998. Potential for selective modulation of glutathione in cancer chemotherapy. Chem Biol Interact 113:112–135.

Diakove SH, Seck J, Champion S, Sayeed A, Mindrinos M, Xiao W, et al. 2008. Bisphenol A induces a profile of tumour aggressiveness in high-risk cells from breast cancer patients. Cancer Res 68:2076–2080.

Dietel P, Di S, Schmidt S, Michna H. 2002. Effects of the environmental estrogens bisphenol A, o,p ‐DDE, p‐tert‐octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol 86:1–70.

Fan M, Bigsby RM, Nephew KP. 2003. The NEDD8 pathway is required for prostate‐mediated degradation of human estrogen receptor (ER) alpha and essential for the anti‐proliferative activity of 18C2,780 in ERAlpha‐positive breast cancer cells. Mol Endocrinol 17:336–355.

Fernandez MF, Arrebola JP, Tsatsoulis J, Navalon A, Ballesteros O, Pulgar R, et al. 2002. Glucuronidation and A‐ and chlorinated derivatives in adipose tissue of women. Reprod Toxicol 24(2):259–264.

Han B, Zhang JT. 2004. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the ATP‐binding cassette transporter ABCG2. Curr Med Chem Anticancer Agents 4(1):43–42.

Hiroi H, Tsutsumi O, Momoeda M, Takai Y, Osuga Y, Takatani Y. 1999. Differential interactions of bisphenol A and 17β-estradiol with estrogen receptor alpha [ERα] and ERβ1a. Endroc Exp J 46:773–778.

Huang Y, Ray S, Need JC, Ibraco AM, Tang C, Nawabi A, et al. 1997. Estrogen increases intracellular p21Waf1/Cip1 and p21Waf1/Cip1 ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 42:73–81.

Hugo ER, Brandebourg TD, Comstock CE, Gersin KS, Sussman JJ, Bonniathan N. 2006. LS14: a novel prostate epithelial cell line that produces proacinar. Endocrinology 147:306–313.

Huppenphen J, Aarnisalo P. 2004. Dimerization modulates the activity of the orphan nuclear receptor ERRgamma. Biochem Biophys Res Commun 314:964–970.

Keri RA, Hu SM, Hunt PA, Knudsen KE, Soto AM, Prins GS. 2007. An evaluation of evidence for the carcinogenic activity of bisphenol A. Reprod Toxicol 24:242–250.

Kulper LG, Lemmen CG, Canim B, Cooke JC, Safe SH, van der Saag PT, et al. 1998. Interaction of estrogenic chemicals and phytosterogens with estrogen receptor beta. Endocrinology 139:452–463.

Kuruto-Niwa R, Tateoka Y, Usuki Y, Nozawa R. 2007. Measurement of bisphenol A concentrations in human colostrum. Chemosphere 66:1160–1164.

Lee HI, Carlson EM, Chua JP, Belcher SM. 2008. Bisphenol A is released from polycarbonate drinking bottles and mimics the neurotoxic actions of estrogen in developing cerebellar neurons. Toxicol Lett 176:149–156.

Long X, Nephew KP. 2006. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-α and -β. Chem 281:907–915.

Marshall DJ. 2004. PeriPrimer: cross-platform, graphical primer design for standard, bisulfite and real-time PCR. Bioinformatics 20(15):2471–2472.

Matsumoto A, Kakuta Y, Terahara Toshih B, Liu X, Ikeda H, et al. 2007. Structural evidence for endocrine disruptor bisphenol A binding to human nuclear receptor ERR gamma. J Biochem 142:517–524.

National Center for Biotechnology Information. 2008. GenBank Overview. Available: http://www.ncbi.nlm.nih.gov/GenBank/ (accessed 18 December 2008).

Oksaka H, Tokunaga T, Liu X, Takayamasi S, Matsushima A, Shingubashi Y. 2008. Direct evidence revealing structural elements essential for the high binding ability of bisphenol A to human estrogen-related receptor-gamma. Environ Health Perspect 116:32–38.

Olsen CM, Meusens-Eholm ET, Samuelsen M, Holme JA, Hongso JK. 2003. Effects of the environmental oestrogens bisphenol A, tetrachlorobisphenol A, tetrabromobisphenol A, 4-hydroxybisphenol and 4,4′-dihydroxybisphenol on estrogen receptor binding, cell proliferation and regulation of oestrogen sensitive proteins in the human breast cancer cell line MCF-7. Pharmacol Toxicol 92:180–188.

Pfaller MW, Horgan DW, Dempke L. 2002. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36.

Prins GS, Birch L, Tang WY, Hu SM. 2007. Developmental estrogen exposures predispose to prostate carcinogenesis with aging. Reprod Toxicol 23:213–218.

Prossnitz ER, Arterburn JB, Sklar LA. 2007. GPR30: A G protein-coupled receptor for estrogen. Mol Cell Endocrinol 265–266:138–142.

Razani M, Pedram A, Levin ER. 2000. Plasma membrane estrogen receptors signal to apoptotic resistance in breast cancer. Mol Endocrinol 14:1344–1347.

Safe SH, Pallaros L, Yoon K, Gaiko D, Ross S, McDonnell D. 2002. Problems for risk assessment of endocrine-active estrogenic compounds. Environ Health Perspect 110(suppl 6):629–925.

Samuelsen M, Olsene C, Holme JA, Meusens-Eholm C, Bergmann A, Hongso JK. 2001. Estrogen-like properties of brominated analogs of bisphenol A in the MCF-10A human breast cancer cell line. Cell Biol Toxicol 17:139–151.

Singleton DW, Feng Y, Yang J, Puga A, Len AV, Khan SA. 2006. Gene expression profiling reveals novel regulation by bisphenol-A in estrogen receptor-alpha-positive human cells. Environ Res 100:86–92.

Soto AM, Sonnenschein C, Chung KL, Fernandez MF, Olea N, Serrano FO. 1995. The E-SCREEN assay as a tool to identify estrogenic chemicals and hormone mimics: a comparison of 265–266:138–142.

Stewart DJ. 2007. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63:12–31.

Teixeira C, Reed JC, Pratt MA. 1995. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving...
Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55:3902–3907.

Thomas P, Dong J. 2006. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J Steroid Biochem Mol Biol 102:175–179.

Tirro E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, et al. 2006. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res 66:4263–4272.

Toso RJ, Jordan MA, Farrell KW, Matsumoto B, Wilson L. 1993. Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine. Biochemistry 32:1285–1293.

Watson CS, Bulayeva NN, Wozniak AL, Finnerty CC. 2005. Signaling from the membrane via membrane estrogen receptor-alpha: estrogens, xenoestrogens, and phytoestrogens. Steroids 70:364–371.

Welshons WV, Nagel SC, Vom Saal FS. 2006. Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure. Endocrinology 147:S56–S69.